Skip to main content
Home

Language & Country Selector for Desktop

language-selector-globe Sandoz | en

Choose Location

  • Americas
  • Asia Pacific
  • Europe
  • International
  • Middle East & Africa
  • Argentina | es
  • Brazil | pt
  • Canada | en
  • Canada | fr
  • Mexico | es
  • United States | en
  • Australia | en
  • Japan | ja
  • Korea | ko
  • Mainland China | zh
  • Austria | de
  • Belgium | fr
  • Belgium | nl
  • Bulgaria | bg
  • Croatia | hr
  • Czech Republic | cs
  • Denmark | da
  • Finland | fi
  • France | fr
  • Germany | de
  • Hungary | hu
  • Italy | it
  • Netherlands | nl
  • Norway | no
  • Poland | pl
  • Portugal | pt
  • Romania | ro
  • Russia | ru
  • Slovakia | sk
  • Spain | es
  • Sweden | sv
  • Switzerland | de
  • Switzerland | fr
  • United Kingdom | en
  • Global | en
  • Sandoz | en
  • Saudi Arabia | ar
  • Turkey | tr

Language & Country Selector for Mobile

language-selector-globe Sandoz

Choose Location

Americas Asia Pacific Europe International Middle East & Africa
  • Argentina | es
  • Australia | en
  • Austria | de
  • Belgium | fr
  • Belgium | nl
  • Brazil | pt
  • Bulgaria | bg
  • Canada | en
  • Canada | fr
  • Croatia | hr
  • Czech Republic | cs
  • Denmark | da
  • Finland | fi
  • France | fr
  • Germany | de
  • Hungary | hu
  • Italy | it
  • Japan | ja
  • Korea | ko
  • Mainland China | zh
  • Mexico | es
  • Netherlands | nl
  • Norway | no
  • Global | en
  • Sandoz | en
  • Poland | pl
  • Portugal | pt
  • Romania | ro
  • Russia | ru
  • Saudi Arabia | ar
  • Slovakia | sk
  • Spain | es
  • Sweden | sv
  • Switzerland | de
  • Switzerland | fr
  • Turkey | tr
  • United Kingdom | en
  • United States | en
    • About Sandoz 
      • Our Purpose and Ambition 
      • What We Do 
      • Innovation, Quality and Supply 
      • Corporate Responsibility 
        • Ethics, Risk and Compliance 
        • Sandoz external funding 
        • Malaria Initiative 
        • Novartis Access 
        • World Child Cancer 
      • Our History 
      • Investor Information 
      A girl with a flower About Sandoz
    • Products & Services 
      • Disease Areas 
        • Anti-Infectives 
        • Respiratory 
        • Endocrinology 
        • Immunology 
        • Oncology 
      • Biopharmaceuticals 
        • Sandoz Biosimilars 
        • Sandoz Biosimilar Portfolio and Pipeline 
        • About Biologics 
        • Development of Biosimilars 
        • Information for Patients 
      • Prescription Medicines 
      • Over-The-Counter Medicines 
      • Partnerships and Collaborations 
        • Business to Business (B2B) 
        • Business to Business (B2B) 
        • Business to Business (B2B) 
      00181_300dpi_RGB Products & Services
    • People & Culture 
      • Sandoz Leadership 
        • Richard Saynor 
        • Francisco Ballester 
        • Martin Bischof 
        • Colin Bond 
        • Pierre Bourdage 
        • Valerie Chew 
        • Claire D'Abreu-Hayling 
        • Glenn A. Gerecke, PhD 
        • Rebecca Guntern 
        • Keren Haruvi 
        • Steffen Kurzawa 
        • Inge Maes 
        • Ingrid Sollerer 
      • Diversity & Inclusion 
      • Associate Stories 
    • Investors & Media 
      • Sandoz spin-off 
      • Media Releases 
      • Media Library 
      • Media Contacts 
      • Novartis Annual Reporting Suite 
    • Careers 
      • Working at Sandoz 
      • Diversity & Inclusion 
      • Associate Stories 
      • Job Search 
      Sandoz Careers Careers
    • News 
      • News Archive 
      • Media Releases 
      • Publications 
      • Stay Up-To-Date 
      A photo of people in a meeting hall News
    • Contacts 
    working at sandoz Home
  1. Home
  2. News
  3. All News
News Archive Navigation
  • All
  • Featured News
  • Media Release
icon
News Archive Navigation Language
  • English
  • French
  • German

June 2022

  • Media ReleaseJun 10, 2022
    HEXAL launches Dimethyl fumarate HEXAL® a generic drug for Tecfidera®, in Germany, offering an economically efficient treatment option for the care of adult patients with multiple sclerosis*
    Dimethyl fumarate HEXAL® is bioequivalent to the originator product 1,2,3 Additional 196 pack size reduces co-payment burden for patients Basel, June 10, 2022 — Sandoz expands its portfolio and…

May 2022

  • Media ReleaseMay 31, 2022
    Sandoz announces new global ‘Act4Biosimilars’ initiative, to improve patient access and increase adoption by at least 30% in 30+ countries by 2030
    Multidisciplinary Steering Committee established to drive action includes patient advocacy leaders, healthcare professionals, biosimilar experts and industry leaders   Action Plan will provide…
  • Media ReleaseMay 27, 2022
    Sandoz appoints new Board representative to global AMR Industry Alliance
    Dr. Boumediene Soufi, global head of Sandoz AMR (antimicrobial resistance) program, to represent Sandoz as Board member of AMR Industry Alliance (AMRIA) The Alliance brings together about 100 life…
  • Media ReleaseMay 12, 2022
    Sandoz launches first generic pirfenidone in US for patients with idiopathic pulmonary fibrosis, growing its respiratory portfolio
    Pirfenidone is used to treat idiopathic pulmonary fibrosis (IPF),1 a progressive disease that causes irreversible lung scarring and makes it difficult to breathe2 Approximately 140,000 Americans…

April 2022

  • Media ReleaseApr 26, 2022
    Novartis delivers solid sales and profit growth. Strong performance of in-market brands supports confidence in mid-term growth outlook
    Ad hoc announcement pursuant to Art. 53 LR Q1 sales grew +5% (cc1, +1% USD), core operating income grew +9% (cc, +3% USD) Innovative Medicines (IM) sales grew +4% (cc, +1% USD) and core operating…
  • Media ReleaseApr 14, 2022
    Sandoz launches generic brimonidine tartrate/timolol maleate eyedrop in US for patients with ocular hypertension, expanding leading ophthalmic portfolio
    Brimonidine tartrate/timolol maleate combination eyedrop is used to treat elevated eye pressure in patients with ocular hypertension1 Ocular hypertension affects over 5% of all adults2; the eye does…
  • Media ReleaseApr 06, 2022
    Sandoz extends collaboration agreement to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR)
    Extending existing master services agreement with Ares Genetics, to develop digital platform for development and life cycle management of antibiotics, to January 31, 2025 Both parties strengthening…

March 2022

  • Media ReleaseMar 14, 2022
    Sandoz targets growth opportunities in respiratory and complex generics through acquisition of respiratory device company Coalesce
    Sandoz gains significant capabilities and assets in medical and drug device development that target major growth opportunities in respiratory and complex generics Respiratory diseases are leading…

February 2022

  • Media ReleaseFeb 18, 2022
    Sandoz launches generic lenalidomide in 19 countries across Europe, expanding access to essential oncology medicine
    Lenalidomide Sandoz is indicated for use in several critical haematology-oncology conditions, per latest ESMO guidelines1,4 Cost savings from Lenalidomide Sandoz can expand treatment options for …
  • Media ReleaseFeb 02, 2022
    Novartis delivers mid single digit sales growth, margin expansion and advancement of robust pipeline in 2021
    Ad hoc announcement pursuant to Art. 53 LR Q4 sales grew +6% (cc1, +4% USD) and core operating income grew +12% (cc, +9% USD) IM sales grew +7% (cc, +5% USD) and core operating income +15% (cc, +…

December 2021

  • Media ReleaseDec 22, 2021
    Sandoz submits Marketing Authorization Application for proposed biosimilar trastuzumab to EMA
    Submission is supported by comprehensive package of analytical, pre-clinical and clinical data, proposed biosimilar trastuzumab developed by EirGenix, Inc. Breast cancer is one of most common types…
  • Media ReleaseDec 20, 2021
    Sandoz submits Biologics License Application for proposed biosimilar trastuzumab to US FDA
    Biologics License Application (BLA) is supported by analytical, pre-clinical and clinical data, proposed biosimilar trastuzumab developed by EirGenix, Inc. Trastuzumab is monoclonal antibody used to…

Pagination

  • ‹ Previous page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • › Next page

Sandoz Global

Key resources
  • Patients & Caregivers
  • Job seekers
  • Investors
  • Media
Recent updates
  • Sandoz spin-off
Explore
  • Contacts
  • Locations
  • Biosimilar Portfolio and Pipeline
Sandoz Companies
  • 1A Pharma
  • Hexal
  • Lek
Footer Bottom
© 2023 Sandoz International GmbH
  • Terms of Use
  • Privacy Policy
  • About Cookies
  • Legal Notice
  • Social Media Community Guidelines
  • Cookie Settings
  • Site Map
  • Web Accessibility
Novartis Site Directory
This site is intended for a global audience